🔗 Share this article

As the United States proceeds with historic revisions to its immunization guidelines, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on COVID-19 shots throughout the global health crisis and has focused upon potential fatalities following Covid immunization in her brief position at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities were set to reveal radical changes to the pediatric immunization program recently, bringing the US with Denmark’s national calendar, according to reports – a major change that would put the US out of alignment with many the international standard with insufficient data for benefit. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to lead the division this calendar year.

A Shift at the Agency

This interim role may indicate a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – traditionally the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

The appointee has no obvious background in medication creation, approval processes or management, which has been typical for past leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the requisite experience” for running the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a major agency. She lacks background in pharmaceutical oversight.”

Former heads of the center would “understand laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who led the center have had.”

This division has an vast workload at the FDA, she emphasized.

“Many people just zeroes in on the innovative therapies, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one have to be looked after,” she said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a significant administrative element to the role, which oversees over 5,000 employees. “It is a enormous management job, if you perform it correctly,” she concluded.

Response and Controversial Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this selection signifies more teamwork among FDA leaders on vaccines, a press secretary stated that the “questions are based on flawed assumptions”.

“Her resume matches the duties of her role,” the official explained, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a contentious rapid medication authorization process that allegedly concerned her former heads. “By what process are these medications being selected for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of pharmaceuticals, except for vaccines.”

Established Past Work on Vaccines

With vaccines, Høeg has a more established, if problematic, track record, critics said. She released a study using unconfirmed crowd-sourced reports to estimate the incidence of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming federal leadership featured revising rules for recently developed shots and halting “unnecessary” immunizations, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from getting Covid vaccinations.

“She is an thorough dogmatist who commences with her conclusions and reverse-engineers to accommodate the data in a extremely deceptive, dishonest fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of other contrarians, {like|